Codexis Inc (NASDAQ:CDXS), Down By 6.52% ($0.14) From $2.193 After BUYINS.NET Report Predicted Weakness After Earnings
February 28, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, February 26th 2013 stating that Codexis Inc (NASDAQ:CDXS) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=cdxs&id=350341
At the time this story was written, Codexis Inc (NASDAQ:CDXS) is Down By 6.52% ($0.14) From $2.193 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
Codexis Inc (NASDAQ:CDXS) - Codexis, Inc. engages in the production of custom industrial enzymes for use in the manufacture of biofuels, chemicals, and pharmaceutical ingredients. The company offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening services, enzyme optimization services, and enzymes, as well as supplies intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, the company develops CodeXyme cellulase enzymes to convert cellulosic biomass, a non-food plant material into affordable sugars, which can then be converted into renewable fuels and chemicals; and CodeXol detergent alcohols that are used to manufacture surfactants, which are used as cleaning ingredients in consumer products, such as shampoos, liquid soaps, and laundry detergents. It intends to market CodeXyme cellulase enzymes to chemicals manufacturers; and CodeXol detergent alcohols as a drop-in substitute for the detergent alcohols market. The company has strategic collaborations with Royal Dutch Shell plc and Iogen Energy Corporation for the production of cellulosic ethanol from wheat straw and corn stover feedstocks. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Codexis Inc (NASDAQ:CDXS) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net